Hoodia xt is a plant based product for the procedure of obesity which is now in clinical development. The product was licensed to Pfizer Inc in 1998 in a global licensing agreement. The cactus from which P57 was created from the hoodia gordoni Cactus plant species.

hoodia xt is a fully specified extract created from a single plant which is subject to patent applications covering raw materials, active substances and mode of action. Hoodia dex l10 gordonii seems to have novel pharmacological properties and may in fact be the first ever true appetite suppressant to be located. Unlike many of the conventional treatments presently available it has no effects on behaviour. The mechanism of action is novel and distinct from those of currently available compounds. Efficacy has been established with a thoughtful weight loss and a utmost emergent safety profile.

hoodia slim considerable progress has been achieved with this project. Phase I of hoodia xt clinical development proceeds alongside an extensive research program. In parallel to these activities, additional plantations for the plant material have been established world-wide in collaboration with the CSIR and Pfizer and a clinical supplies unit, dedicated to the manufacturer of the material, has been opened in South Africa.

Anecdotal reports of the use of hoodia xt in humans reveal that it significantly reduces appetite, food intake and body weight. Considerable work has been undertaken to fractionate this plant material and a number of compounds have been isolated from the mixture, some of which have biological activity. The mechanism of action of P57 and its active constituents is currently under investigation. Additional pharmacological properties have currently been established.

hoodia xt is an appetite suppressant with novel pharmacological properties that has no effects on behavior. It is pulled from the hoodia gordonii complex, a South African plant which has been eaten by Bushmen for thousands of years to curb off thirst and hunger during long hunting trips. Phytopharm has six patents in progress covering the use of the plant, its active molecules, derivatives and mode of action. Once its patents are published the company will disclose the mode of action. Last year Dr. Richard Dixey, CEO of Phytopharm, told the Wall Street Transcript, “We will not disclose the mode of action at this time because hoodia xt is the subject of a very active patenting program. There is no point in early disclosure of such information until the patent is eventually undertaken and the information enters the public domain. All one would be doing would be to give ones power competitors useful information and suggest that people to cheap hoodia“.

“Disclaimer: This article is just for informational purposes. Always consult your medical doctor before following the advice stated”